ArticleNPJ precision oncology2025
ACTG1 driven splicing of P4HB gene enhances EMT and bladder cancer progression.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bladder cancer (BLCA) remains a major health challenge due to its high incidence and poor prognosis. This study delves into the role of Actin Gamma 1 (ACTG1) in modulating the splicing of the P4HB gene, leading to the formation of the circular RNA circ_0046263, and its impact on epithelial-mesenchymal transition (EMT) and BLCA progression. Utilizing transcriptome and clinical data from The Cancer Genome Atlas (TCGA) and splicing data from the TCGA SpliceSeq database, we identified survival-associated splicing events through least absolute shrinkage and selection operator (LASSO) regression and Cox analysis. A meta-analysis of BLCA-related mRNA sequencing datasets from the gene expression omnibus (GEO) database validated the differential expression of ACTG1. Immune infiltration analysis and circRNA sequencing data revealed significant upregulation of ACTG1 in BLCA, correlating with various immune cells and checkpoints. Functional assays confirmed that ACTG1 promotes the splicing of P4HB to form circ_0046263, enhancing BLCA cell proliferation, migration, and invasion. Silencing ACTG1 in vivo suppressed tumor growth and metastasis, effects that were reversed by overexpression of circ_0046263. These findings highlight the pivotal role of ACTG1 in regulating EMT in BLCA through its splicing activity on P4HB, suggesting new therapeutic targets for intervention. This study underscores the critical importance of splicing regulation in cancer biology, offering novel insights for diagnostic and therapeutic strategies in BLCA.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.